CONCISE REPORT

Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis

D N Kiortsis¹, A K Mavridis², S Vasakos², S N Nikas³, A A Drosos³

¹ Laboratory of Physiology, Medical School, University of Ioannina, Ioannina, Greece
² Laboratory of Microbiology, General Hospital of Ioannina, Ioannina, Greece
³ Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece

Correspondence to:
Professor A A Drosos
Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece; adrosos{at}cc.uoi.gr

Background: Tumour necrosis factor (TNF) may be an important mediator of insulin resistance. Infliximab is a chimeric monoclonal, high affinity antibody against the soluble and transmembrane TNF, which can reduce markedly the biological activity of circulating and tissue TNF and is used to treat various autoimmune disorders.

Objective: To assess the effects of infliximab infusions on insulin sensitivity in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS).

Methods: 45 patients (28 with RA, 17 with AS) aged 19–74 years were studied. All patients were treated with intravenous infliximab. A complete biochemical profile was obtained before and after 6 months’ treatment with infliximab. The Homoeostasis Model Assessment (HOMA) Index was used to measure insulin resistance and the Quantitative Insulin Sensitivity Check Index (QUICKI) to measure insulin sensitivity.

Results: In the whole study group, no significant changes of the HOMA Index or QUICKI were seen. In the tertile of patients with the highest insulin resistance, a significant decrease of the HOMA Index and increase of the QUICKI was found (p<0.01 for both).

Conclusions: The results suggest that infliximab treatment may have beneficial effects on insulin sensitivity in the most insulin resistant patients with RA and AS.

Abbreviations: AS, ankylosing spondylitis; CVD, cardiovascular disease; DMARDs, disease modifying antirheumatic drugs; HOMA, Homoeostasis Model Assessment; QUICKI, Quantitative Insulin Sensitivity Check Index; RA, rheumatoid arthritis; TNF, tumour necrosis factor

Keywords: ankylosing spondylitis; infliximab; insulin resistance; rheumatoid arthritis; tumour necrosis factor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• van Halm, V P, Peters, M J L, Voskuyl, A E, Boers, M, Lems, W F, Visser, M, Stehouwer, C D A, Spijkerman, A M W, Dekker, J M, Nijpels, G, Heine, R J, Bouter, L M, Smulders, Y M, Dijkmans, B A C, Nurmohamed, M T (2009). Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 68: 1395-1400 [Abstract] [Full Text]  
• Wijbrandts, C A, van Leuven, S I, Boom, H D, Gerlag, D M, Stroes, E G S, Kastelein, J J P, Tak, P P (2009). Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis 68: 1316-1321 [Abstract] [Full Text]  
• Steinberg, G. R., Kemp, B. E. (2009). AMPK in Health and Disease. Physiol. Rev. 89: 1025-1078 [Abstract] [Full Text]  
• Lee, D.-E., Kehlenbrink, S., Lee, H., Hawkins, M., Yudkin, J. S. (2009). Getting the message across: mechanisms of physiological cross talk by adipose tissue. Am. J. Physiol. Endocrinol. Metab. 296: E1210-E1229 [Abstract] [Full Text]  
• Maury, E., Noel, L., Detry, R., Brichard, S. M. (2009). In Vitro Hyperresponsiveness to Tumor Necrosis Factor-{alpha} Contributes to Adipokine Dysregulation in Omental Adipocytes of Obese Subjects. J. Clin. Endocrinol. Metab. 94: 1393-1400 [Abstract] [Full Text]  
• Montecucco, F., Mach, F. (2009). Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 48: 11-22 [Abstract] [Full Text]  
• Zu, L., Jiang, H., He, J., Xu, C., Pu, S., Liu, M., Xu, G. (2008). Salicylate Blocks Lipolytic Actions of Tumor Necrosis Factor-{alpha} in Primary Rat Adipocytes. Mol. Pharmacol. 73: 215-223 [Abstract] [Full Text]  
• Dixon, W G, Symmons, D P M (2007). What effects might anti-TNF{alpha} treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF{alpha} in cardiovascular pathophysiology. Ann Rheum Dis 66: 1132-1136 [Abstract] [Full Text]  
• Lo, J., Bernstein, L. E., Canavan, B., Torriani, M., Jackson, M. B., Ahima, R. S., Grinspoon, S. K. (2007). Effects of TNF-{alpha} neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am. J. Physiol. Endocrinol. Metab. 293: E102-E109 [Abstract] [Full Text]  
• Huvers, F. C, Popa, C., Netea, M. G, van den Hoogen, F. H J, Tack, C. J (2007). Improved insulin sensitivity by anti-TNF{alpha} antibody treatment in patients with rheumatic diseases. Ann Rheum Dis 66: 558-559 [Full Text]  
• van Eijk, I C, Peters, M J L, Nurmohamed, M T, van Deutekom, A W, Dijkmans, B A C, Simsek, S (2007). Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis. Eur J Endocrinol 156: 291-293 [Abstract] [Full Text]  
• Karvounaris, S A, Sidiropoulos, P I, Papadakis, J A, Spanakis, E K, Bertsias, G K, Kritikos, H D, Ganotakis, E S, Boumpas, D T (2007). Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann Rheum Dis 66: 28-33 [Abstract] [Full Text]  
• Trujillo, M. E., Scherer, P. E. (2006). Adipose Tissue-Derived Factors: Impact on Health and Disease. Endocr. Rev. 27: 762-778 [Abstract] [Full Text]  
• Yazdani-Biuki, B., Mueller, T., Brezinschek, H.-P., Hermann, J., Graninger, W., Wascher, T. C. (2006). Relapse of Diabetes After Interruption of Chronic Administration of Anti-Tumor Necrosis Factor-{alpha} Antibody Infliximab: A case observation. Diabetes Care 29: 1712-1713 [Full Text]  
• Sarzi-Puttini, P, Atzeni, F, Scholmerich, J, Cutolo, M, Straub, R H (2006). Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. Ann Rheum Dis 65: 301-305 [Abstract] [Full Text]